Home Cart Sign in  
Chemical Structure| 928659-70-5 Chemical Structure| 928659-70-5

Structure of Eliglustat hemitartrate
CAS No.: 928659-70-5

Chemical Structure| 928659-70-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Eliglustat tartrate, a specific inhibitor of glucosylceramide synthase, is under development as an oral substrate reduction therapy for Gaucher disease type 1 (GD1).

Synonyms: Eliglustat tartrate; Genz-112638; Eliglustat (hemitartrate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Eliglustat hemitartrate

CAS No. :928659-70-5
Formula : C50H78N4O14
M.W : 959.17
SMILES Code : CCCCCCCC(N[C@H](CN1CCCC1)[C@@H](C2=CC=C(OCCO3)C3=C2)O)=O.CCCCCCCC(N[C@H](CN4CCCC4)[C@@H](C5=CC=C(OCCO6)C6=C5)O)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O
Synonyms :
Eliglustat tartrate; Genz-112638; Eliglustat (hemitartrate)
MDL No. :MFCD22665712
InChI Key :KUBARPMUNHKBIQ-VTHUDJRQSA-N
Pubchem ID :52918379

Safety of Eliglustat hemitartrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01074944 Gaucher Disease PHASE3 COMPLETED 2025-10-15 University of California, San ... More >>Diego Medical Center, San Diego, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Emory University Medical Center, Decatur, Georgia, United States|Children's Memorial Hospital, Chicago, Illinois, United States|Mount Sinai Medical Center, New York, New York, United States|New York University School of Medicine, New York, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States|O and O Alpan LLC, Springfield, Virginia, United States|Royal Prince Alfred Hospital, Camperdown, Australia|Monash Medical Centre, Clayton, VIC, Australia|Royal Perth Hospital, Perth, WA, Australia|Medical University Vienna, Vienna, Austria|Hospital das Clinicas da UFMG, Belo Horizonte, Brazil|Cettro - Centro de Tratamento de Oncologia e Hematologia, Brasília, Brazil|Hemocentro - UNICAMP, Campinas, Brazil|Instituto Tropical de Medicina Reprodutiva e Menopausa - INTRO, Cuiaba, Brazil|Hospital Universitario Walter Cantidio - HUWC, Fortaleza, Brazil|Hemocentro de Ribeir?o Preto Núcleo de Hemoterapia de Franca, Franca, Brazil|Hemorio, Rio de Janeiro, Brazil|Hospital de Clínicas da Universidade Federal do Parana, Sao Paulo, Brazil|IGEIM - Institute of Genetic and Inborn Erros of Metabolism, Sao Paulo, Brazil|Mount Sinai Hospital, Toronto, Canada|Peking Union Medical College Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|Shanghai Xinhua Hospital Shanghai Xinhua Hospital, Shanghai, China|Tianjin Hematonosis Hospital, Tianjin, China|University Hospital Centre Zagreb, Zagreb, Croatia|H?pital Haut Lévêque, Bordeaux, France|H?pital Femme Mère Enfant Centre de référence des maladies Héréditaires du métabolisme, Bron, France|General Hospital of Athens "G. Gennimatas", Athens, Greece|King Edward Memorial (KEM) Hospital, Mumbai, India|Hiroshima University Hospital, Hiroshima, Japan|Jikei University Hospital, Tokyo, Japan|Juntendo University Hospital, Tokyo, Japan|Mie Chuou Medical Center, Tsu, Mie, Japan|Academic Medical Center, Amsterdam, Netherlands|Hospital de Santa Maria, Lisboa, Portugal|Hospital do Divíno Espírito Santo, Ponta Delgada - S?o Miguel - A?ores, Portugal|Spitaulu Clinic de Urgenta, Cluj-Napoca, Romania|State Medical and Prophylactic Healthcare Institution; Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russian Federation|Hematology Research Center of Russian Academy of Medical Sciences, Moscow, Russian Federation|St. Petersburg State Medical Pavlov University, St. Petersburg, Russian Federation|Clinical Centre of Serbia, Belgrade, Serbia|University Hospital Lund, Lund, Sweden Less <<
NCT00358150 Gaucher Disease, Type 1|Cerebr... More >>oside Lipidosis Syndrome|Glucocerebrosidase Deficiency Disease|Glucosylceramide Beta-Glucosidase Deficiency Disease|Gaucher Disease, Non-Neuronopathic Form Less << PHASE2 COMPLETED 2025-12-15 New York University, New York,... More >> New York, United States|New York, New York, United States|Aprillus Asistencia e Investigación, Buenos Aires, Argentina|Hospital de Oncologia Maria Curie, Buenos Aires, Argentina|IMAI, Buenos Aires, Argentina|Instituto Argentino de Diagnostico y Tratamiento (IADT), Buenos Aires, Argentina|Buenos Aires, Argentina|Hospital Ramos Mejia, Ciudad Autonoma de Buenos Aires, Argentina|Rambam Medical Center, Haifa, Israel|Haifa, Israel|Sha'are Zedek Medical Centre, Jerusalem, Israel|Jerusalem, Israel|Universita degli Studi di Milano, Milano, Italy|Instituto Mexicano del Seguro Social, D.f., Mexico|Mexico City, Mexico|Hematology Research Center of Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation|Moscow, Russian Federation Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.04mL

0.21mL

0.10mL

5.21mL

1.04mL

0.52mL

10.43mL

2.09mL

1.04mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories